易瑞沙治疗化疗失败非小细胞肺癌的临床观察

为评估易瑞沙(IRESSA)治疗化疗失败的非小细胞肺癌(NSCLC)的临床效果和毒副反应,2004年1月~2005年4月对31例曾经一线化疗治疗失败的NSCLC患者推荐给予易瑞沙250mg,口服,1次/d,结果总有效率(RR)41·9%(13/31),临床受益率(CBR)64·5%(20/31),常见毒副反应为食欲减退、轻度腹泻、皮疹和痤疮。1例患者死于重症间质性肺病变。初步的临床观察结果显示,易瑞沙对于一线化疗失败或化疗无效的晚期NSCLC肯定有效,能较好地缓解疾病相关症状,毒副反应轻微,大多可耐受。

Clinical observation on IRESSA for previously treated patients with non-small cell lung cancer

To evaluate the efficacy and toxicities/side effects of IRESSA for non-small cell lung cancer (NSCLC), 31 patients with NSCLC, who failed to first-line chemotherapy, were introduced to IRESSA 250mg, p.o., daily, from January 2004 to April 2005. The result was the total effective rate of 41.9% (13/31), the clinic benefit of 64.5% (20/31). The common adverse drug reactions (ADRs) were anorexia, mild diarrhea, skin rash, acne etc. One patient died of severe interstitial lung disease. In preliminary conclusion, we make sure that IRESSA is feasible for patient with advanced NSCLC, who had been administered by first-line or invalid chemotherapy, and provides unprecedented clinically meaningful and durable antitumor activity. This drug can retieve disease-related symptoms, with well-tolerated, mild adverse events.